Phase 3 study of avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC)
Keyword(s):
Phase 3
◽
2015 ◽
Vol 16
(13)
◽
pp. 1915-1927
◽
2020 ◽
Vol 36
(9)
◽
pp. 1507-1517
Keyword(s):
2018 ◽
Vol 34
(10)
◽
pp. 457-465
◽
Keyword(s):
Keyword(s):